Beta-Galactoside-Binding Lectin for Embryo Implantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
High rates of early embryo loss in livestock due to maternal-fetal immune rejection, leading to economic losses in agricultural industries, particularly in reproductive techniques like mating, artificial insemination, in vivo, and in vitro fertilization, where embryos are often rejected due to lack of maternal-fetal tolerance.
Innovation Solution
Administering an effective amount of beta-galactoside-binding lectin, such as Galectin-1, to the uterus of mammals to enhance embryo implantation rates by promoting immune tolerance and adhesion, thereby reducing embryo rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reproduction techniques (mating, artificial insemination, embryo transfer) are used, then genetic improvement and productivity can be achieved, but high rates of early embryo loss occur due to maternal-fetal immune rejection
Solution Approach 1:
The patent uses beta-galactoside-binding lectin (such as Galectin-1) as an intermediary substance to mediate between the maternal immune system and the embryo. The lectin binds to beta-galactoside residues on embryo surface glycans, acting as a molecular bridge that promotes immune tolerance and prevents maternal rejection of the embryo, thereby improving implantation rates without interfering with conventional reproduction techniques
Solution Approach 2:
The patent changes the biochemical parameters of the uterine environment by introducing exogenous beta-galactoside-binding lectin. This lectin modifies the glycan-lectin interaction landscape in the uterus, creating favorable conditions for embryo attachment and immune tolerance. The treatment alters the molecular recognition patterns between maternal immune cells and embryo surface markers, shifting the immune response from rejection to acceptance
2Adaptability or versatility
If embryos with foreign genetic material are introduced through assisted reproduction techniques, then genetic diversity and improvement are achieved, but maternal-fetal tolerance is compromised leading to embryo rejection
Solution Approach 1:
The patent converts the harmful immune recognition of foreign embryo genetic material into a beneficial outcome. By introducing beta-galactoside-binding lectin, the system exploits the embryo's surface glycans (which normally trigger immune rejection) as binding targets for the lectin. This interaction masks the foreign genetic markers and actively promotes immune tolerance, transforming the rejection mechanism into a protection mechanism that supports embryo survival
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases embryo implantation rates in the uterus, improving reproductive efficiency and reducing economic losses by enhancing the survival and growth of embryos, leading to improved productivity and reduced reproductive expenses.
Implementation Method 1
beta-galactoside-binding lectin or derivatives thereof... Galectin-1, Galectin-3, Galectin-9, Galectin-13 or Galectin-15... binding to beta-galactoside residues
Data Source
AI summary
The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.